In obesity trials, the Wegovy pill showed slightly greater weight loss, and fewer patients stopped treatment due to side effects
4 from October 23, 2013)
However, there are many drawbacks that commercials and marketing campaigns dont tell you
First, we emulated the two cardiovascular outcome trials SUSTAIN-6 (semaglutide versus placebo) and SURPASS-CVOT (tirzepatide versus dulaglutide) using the RCT-DUPLICATE approach to benchmark findings and inform the study design and analytic approach for expanded questions
"Offering Zepbound single-dose vialsthe most affordable branded incretin medicine by list pricethrough another platform to LillyDirect will help ensure broader availability of rigorously tested, FDA-approved and regulated obesity treatment," said Patrik Jonsson, executive vice president, and president of Lilly Cardiometabolic Health and Lilly USA in a statement
A facility can hold GMP certification for its pharmaceutical product lines while running a separate, less controlled production line for research-grade peptides
